Literature DB >> 8610782

Jelly beans as an alternative to a cola beverage containing fifty grams of glucose.

K L Boyd1, E K Ross, S J Sherman.   

Abstract

OBJECTIVE: Our purpose was to test the diagnostic value and patient tolerance of jelly beans as an alternative to a 50 gm glucose solution. STUDY
DESIGN: Pregnant women between 26 to 30 weeks of gestation confirmed by early ultrasonography were recruited to participate in the study. Each participant was given a cola beverage containing 50 gm of glucose. The plasma glucose level was determined 1 hour later. Within 2 weeks of the 50 gm glucose test, each patient ate 18 jelly beans and had her plasma glucose levels tested after 1 hour. Finally, within 2 weeks of the jelly bean test a 100 gm, 3-hour glucose tolerance test was performed on each subject. The results of the 3-hour test were used to define the presence or absence of gestational diabetes and carbohydrate intolerance by the criteria of The American College of Obstetricians and Gynecologists. Patient tolerance was rated by responses to questions regarding side effects.
RESULTS: One hundred fifty-seven women completed the study. The mean maternal age, gravidity, parity, and number of abortions were 26.06 years, 2.66, 0.96, and 0.69. By use of a 140 mg/dl threshold, the sensitivity, specificity, and positive predictive value of the cola beverage was 46%, 81%, and 18%. These values at a 120 mg/dl threshold for jelly beans were 54%, 81%, and 20%, respectively. The patient tolerance was greater for the jelly beans compared with the 50 gm cola beverage.
CONCLUSION: Jelly beans may serve as an alternative to a cola beverage containing 50 gm of glucose.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8610782     DOI: 10.1016/0002-9378(95)90447-6

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  1 in total

1.  Twizzlers as a cost-effective and equivalent alternative to the glucola beverage in diabetes screening.

Authors:  Diana A Racusin; Nellie S Crawford; Sara Andrabi; Melissa A Suter; Haleh Sangi-Haghpeykar; Lori Showalter; Susan Sharma; Morey Haymond; Kjersti M Aagaard
Journal:  Diabetes Care       Date:  2013-10       Impact factor: 19.112

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.